Author(s)

Mamadou Wague Gueye^1*, Nata Dieng², Maguette Ndoye¹, Mor Ngom¹, Sokhna Moumi Mbacké Daffé¹, Papa Silman Diawara¹, Macoura Gadji³, Ndèye Marième Diagne², Bécaye Fall¹

¹Laboratory Federation, Hôpital Principal de Dakar (HPD), Dakar, Senegal.
²Onco-Hematology, Hôpital Principal de Dakar (HPD), Dakar, Sénégal.
³Biological and Oncological Hematology Department (BOHD), Centre National de Transfusion Sanguine (CNTS)/FMPOS-UCAD, Dakar, Sénégal.

Multiple myeloma (MM) is both a complex and heterogeneous disease. Cytogenetic and molecular abnormalities lead to resistance to treatment and transformation to plasma cell leukemia, which is defined by the presence in circulating blood of plasma cells over 2 G/L, or more than 20% of leukocytes. It is an uncommon hematological malignancy with a poor prognosis. Against this backdrop, we report an observation of multiple myeloma transformed into plasma cell leukemia diagnosed at the Hôpital Principal de Dakar (HPD) that occurred on a 64-year-old man with a history of thyroidectomy followed for multiple myeloma presenting with Salmon et Durie stage IIIA and ISS stage I. Despite a marked improvement in management strategy, myeloma remains an almost invariably incurable disease. However, the development of genetic and molecular biomarkers is necessary to improve its prognosis.

Multiple Myeloma, Plasma Cells Leukemia, Personalized Medicine, Risk Stratification

Gueye, M. , Dieng, N. , Ndoye, M. , Ngom, M. , Daffé, S. , Diawara, P. , Gadji, M. , Diagne, N. and Fall, B. (2023) From Myeloma to Plasma Cell Leukemia, Persistent Inequalities. Open Journal of Blood Diseases, 13, 133-140. doi: 10.4236/ojbd.2023.134015.